→ OvaScience struggled hard last year, dropping its CEO, COO and 30% of its staff. Now they have named a new CEO, Christopher Kroeger. Kroeger previously spent over a decade at the venture firm The Aurora Funds, and before that he ran Cardioxyl, which was sold to Bristol-Myers in 2015 for its heart failure drug. Co-founder and Chairman Michelle Dipp, who stepped in to helm the company during its turbulence, is now taking an advisory role with the fertility company.
→ Billionaire hedge funder John Paulson has been elected to the board of directors at Valeant. Chairman and CEO Joseph Papa says in a statement that “with his significant business and financial expertise, John will be a strong addition to the board. His experience will be especially valuable as we continue to execute on our transformational strategy to turnaround Valeant.” Paulson has reportedly lost nearly $2B from his stake in Valeant.
→ Helén Tuvesson is transitioning from CSO to CEO of Active Biotech AB. She is replacing CEO Tomas Leanderson, who has led the Swedish company since 2008.
→ The founder, president, CEO, and chairman of the board at Five Prime, Lewis “Rusty” Williams will be shedding a couple of those titles sometime in 2018 after the company grabs a new CEO. Williams will take on the executive chairman role and become part of the scientific advisory board once the search is complete.
→ Biogen has recruited Ginger Gregory as their new chief human resources officer, who stepped away from the exact same position at Shire.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 19,000+ biopharma pros who read Endpoints News by email every day.Free Subscription